EPIX: ESSA Pharma Company Buyout Price

ESSA Pharma Inc. (EPIX) acts as a biopharmaceutical innovator, developing unique inhibitors to combat hormone-dependent tumors through extensive R&D investments. The share price illustrated below, which stands at , correlates with the development of prostate cancer treatments and plans for their market launch. However, the termination of key trials due to poor efficacy has created critical risks, forcing management to urgently seek ways to preserve capital.

EPIX ESSA Pharma Inc.: Enterprise Value in the range 07/04/2022 - 10/28/2026

EPIX (ESSA Pharma): analytical breakdowns and indicator data

- price and consensus price forecast:

Quote Chart ESSA Pharma, Inc.|EPIX - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization ESSA Pharma|EPIX - Real Price to Acquire Entire Company

- book capitalization data:

Equity per Share ESSA Pharma|EPIX - Book Capitalization|Market Cap to Net Assets Ratio essapharma.com|EPIX - Company Total Assets

- debt and liquidity data:

Total Debt to Capital ESSA Pharma Inc.|EPIX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio ESSA Pharma, Inc.|EPIX - Company Aggregate Debts|Debt to Book Value ESSA Pharma

Fundamental company valuation:EPIX (ESSA Pharma Inc.)

Manufactured products of ESSA Pharma Inc.

For the biotech sector, where ESSA Pharma Inc. (EPIX) develops long-term patents for endocrine tumor therapies, the enterprise value chart serves as an indicator of the actual buyout price. This metric represents the total value of the company, combining market capitalization and net debt. The calculation is based on the sum of equity and liabilities minus available liquidity. This mechanism allows for an assessment of the actual costs to acquire all of the company's assets. This helps the investor determine the fair value of the business, accounting for its debt load.

Direct competitors